Seven Grand Managers LLC Acquires New Shares in Viridian Therapeutics, Inc. $VRDN

Seven Grand Managers LLC acquired a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 100,000 shares of the company’s stock, valued at approximately $3,112,000.

Other large investors have also made changes to their positions in the company. Aster Capital Management DIFC Ltd bought a new stake in shares of Viridian Therapeutics in the 3rd quarter valued at $35,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Viridian Therapeutics in the 4th quarter valued at $36,000. Bessemer Group Inc. increased its position in shares of Viridian Therapeutics by 947.7% in the 3rd quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock valued at $45,000 after buying an additional 1,886 shares in the last quarter. Larson Financial Group LLC bought a new stake in shares of Viridian Therapeutics in the 3rd quarter valued at $52,000. Finally, US Bancorp DE increased its position in shares of Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after buying an additional 463 shares in the last quarter.

Analyst Ratings Changes

A number of analysts recently commented on VRDN shares. Truist Financial lowered their price objective on shares of Viridian Therapeutics from $36.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Needham & Company LLC restated a “buy” rating and issued a $32.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, May 5th. Wells Fargo & Company lowered their price objective on shares of Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 31st. Royal Bank Of Canada upped their price objective on shares of Viridian Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Finally, Stifel Nicolaus set a $39.00 target price on Viridian Therapeutics in a report on Wednesday, May 13th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Viridian Therapeutics has an average rating of “Moderate Buy” and an average price target of $36.14.

Viridian Therapeutics Price Performance

VRDN stock opened at $17.26 on Thursday. The stock has a 50-day moving average price of $18.17 and a two-hundred day moving average price of $26.31. The stock has a market cap of $1.78 billion, a PE ratio of -5.20 and a beta of 0.82. The company has a current ratio of 15.15, a quick ratio of 15.15 and a debt-to-equity ratio of 0.10. Viridian Therapeutics, Inc. has a 1 year low of $13.18 and a 1 year high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.16. The firm had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.04 million. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The company’s revenue was up 95.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.87) EPS. Equities analysts forecast that Viridian Therapeutics, Inc. will post -3.71 EPS for the current fiscal year.

Insider Transactions at Viridian Therapeutics

In other news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the stock in a transaction on Monday, May 11th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $19,999,990.00. Following the acquisition, the director owned 5,090,928 shares in the company, valued at approximately $86,545,776. This trade represents a 30.05% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 2.40% of the company’s stock.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.